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Resolution of Clinical and Laboratory Abnormalities after Diagnosis of
Ventilator-Associated Pneumonia in Trauma Patients
Abstract
Background: Guidelines advise that patients with ventilator-associated pneumonia (VAP) should respond
clinically by Day 3 of antibiotics. White blood cell (WBC) count, maximum temperature (Tmax), and
PaO2:FIO2 ratio are all said to respond significantly by Day 6. Resolution of abnormalities has not been
evaluated in trauma patients.
Methods: Retrospective review of trauma patients with VAP. The WBC count, Tmax, and PaO2:FIO2 were
evaluated for 16 days after diagnosis. Patients were grouped into uncomplicated VAP, complicated VAP (those
with inadequate empirical therapy [IEAT], VAP relapse/superinfection, or acute respiratory distress
syndrome), and concurrent infection +VAP (those also infected at another site).
Results: There were 126 patients (uncomplicated VAP= 29, complicated VAP = 69, and concurrent infection
+ VAP = 28). The mean Tmax in patients with uncomplicated VAP decreased significantly from diagnosis to
Day 4 (Day 1: 39 – 0.5°C vs. Day 4: 38.6 – 0.7°C; p = 0.028) but never normalized. Their WBC counts and
PaO2:FIO2 did not change significantly over the 16-day follow-up and never normalized.When comparing
the three groups, the probability of resolving all three abnormalities was not different (p = 0.5).
Conclusions: Clinical and laboratory abnormalities in critically injured patients with VAP do not resolve as
quickly as suggested in the guidelines. Future studies should evaluate new methods to determine the response
to antibiotic therapy in critically injured patients with VAP.
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Resolution of Clinical and Laboratory Abnormalities
after Diagnosis of Ventilator-Associated Pneumonia
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Abstract
Background: Guidelines advise that patients with ventilator-associated pneumonia (VAP) should respond clinically
by Day 3 of antibiotics. White blood cell (WBC) count, maximum temperature (Tmax), and PaO2:FIO2 ratio are all
said to respond significantly by Day 6. Resolution of abnormalities has not been evaluated in trauma patients.
Methods: Retrospective review of trauma patients with VAP. The WBC count, Tmax, and PaO2:FIO2 were
evaluated for 16 days after diagnosis. Patients were grouped into uncomplicated VAP, complicated VAP (those
with inadequate empirical therapy [IEAT], VAP relapse/superinfection, or acute respiratory distress syndrome),
and concurrent infection +VAP (those also infected at another site).
Results: There were 126 patients (uncomplicated VAP = 29, complicated VAP= 69, and concurrent infection +
VAP = 28). The mean Tmax in patients with uncomplicated VAP decreased significantly from diagnosis to Day 4
(Day 1: 39 – 0.5C vs. Day 4: 38.6 – 0.7C; p = 0.028) but never normalized. Their WBC counts and PaO2:FIO2 did
not change significantly over the 16-day follow-up and never normalized. When comparing the three groups, the
probability of resolving all three abnormalities was not different (p = 0.5).
Conclusions: Clinical and laboratory abnormalities in critically injured patients with VAP do not resolve as
quickly as suggested in the guidelines. Future studies should evaluate new methods to determine the response to
antibiotic therapy in critically injured patients with VAP.
Ventilator-associated pneumonia (VAP) is the mostcommon serious infection in critically ill, mechanically
ventilated patients and carries a high mortality rate (33%–
50%) [1]. It is essential to treat VAP appropriately with
antibiotics and evaluate a patient’s response to therapy by
monitoring for improvement or normalization of clinical
signs, including temperature, white blood cell (WBC) count,
and PaO2:FIO2 ratio. Such monitoring is crucial because
non-response may indicate suboptimal treatment or a drug-
resistant pathogen. Current guidelines advise that appropri-
ately treated patients should have a good clinical response by
Day 3 and a substantive improvement by Day 6 [1]. These
recommendations are based mainly on expert opinion and
two studies [2,3] in which clinical improvement occurred by
Days 3–5, as judged primarily by WBC count, maximum
temperature (Tmax), and PaO2:FIO2. Using these guidelines,
some practitioners initiate empirical antibiotics for clinical
suspicion of VAP and then use a good clinical response to
confirm the diagnosis.
However, trauma patients are a unique population that
may respond to VAP treatment differently than do general
medical/surgical intensive care unit (ICU) patients. Trau-
matic injury can induce the systemic inflammatory response
syndrome (SIRS), contributing to derangements of clinical
measures used to determine the response to VAP therapy. As
many as 91% of trauma patients exhibit signs of SIRS during
the first week in the ICU [4]. In addition, a composite score of
clinical measures (Clinical Pulmonary Infection Score
[CPIS]) used for VAP diagnosis in some medical ICUs does
not perform well in critically injured patients, making it a
poor choice for evaluating the response to therapy [5].
We hypothesized that clinical and laboratory abnormalities
in patients with no confounders would decline significantly
after VAP, whereas those in patients with confounders would
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stay elevated throughout follow-up. Additionally, because
there are insufficient data to characterize the clinical and la-
boratory response to VAP in critically injured patients, we
evaluated the resolution of clinical and laboratory abnor-
malities retrospectively in these patients after diagnosis and
appropriate treatment of VAP.
Patients and Methods
Following approval by the University of Tennessee In-
stitutional Review Board (IRB number 09-00277-XM), this
retrospective review was conducted at the Presley Memorial
Trauma Center, Memphis, TN. Patients admitted from De-
cember 1, 2006, through July 31, 2008, were eligible if they
were ‡ 18 years of age and had VAP diagnosed. Patients who
died during treatment were excluded, as their elevated values
prior to death could mask overall resolution in the group.
Patients receiving steroids also were excluded in order to
avoid misinterpretation of Tmax and WBC count.
Diagnosis and treatment of VAP
Ventilator-associated pneumonia was suspected if pa-
tients had a new or changing infiltrate on chest radiograph
and experienced two of the following clinical signs: fever or
hypothermia ( > 38C or < 36C), leukocytosis or leukopenia
( > 10 · 103 cells/mm3 or < 4 · 103 cells/mm3), or macro-
scopically purulent sputum. The VAP diagnosis was con-
firmed using bronchoscopic bronchoalveolar lavage (BAL)
with quantitative culture demonstrating bacterial growth
‡ 100,000 colony-forming units (CFU)/mL. Empirical antibi-
otic therapy was initiated in all patients immediately after the
BAL. All patients were treated for suspected VAP using a
unit-specific protocol [5,6–8]. Thus, patients admitted to the
trauma intensive care unit (TICU) for £ 7 days received am-
picillin/sulbactam 3 g intravenously (IV) every 6 h, or moxi-
floxacin 400mg IV every 24 h in those with penicillin allergy.
Patients mechanically ventilated for ‡ 7 days received van-
comycin 20mg/kg IV q 12 h plus cefepime 2 g IV q 8h, or
ciprofloxacin 400mg IV q 8h for those with penicillin allergy.
On identification of the causative pathogen, antibiotic therapy
was narrowed appropriately. Based on previous data, the
treatment protocol dictates that patients with early VAP ( < 7
days) be treated for seven days [7]. For late VAP, the protocol
recommends a follow-up BAL to determine microbiologic
response to antibiotic therapy, if possible. A follow-up BAL
demonstrating growth of the original pathogen of < 10,000
CFU/mL is deemed a microbiologic response. If growth is
10,000–99,999 CFU/mL, antibiotics are continued for the
maximum duration to ensure appropriate treatment. If cul-
ture of an organism yields ‡ 100,000 CFU/mL, the BAL
finding is deemed a relapse or superinfection (depending on
the original pathogen). The protocol recommends amaximum
duration of therapy of 14 days for late pathogens such as
methicillin-resistant Staphylococcus aureus (MRSA), Pseudo-
monas aeruginosa, or Acinetobacter baumannii [9]. If patients’
signs and symptoms are not resolving while the patient is
being treated, the protocol recommends continuing to search
for new or recurrent infections as indicated (subsequent BALs,
blood cultures, urine cultures, etc.). If the signs of VAP are not
resolved at the end of antibiotic therapy, antibiotics are
stopped, and the search for occult infections continues. Ex-
treme cases such as hemodynamic instability could warrant
continuation of antibiotics, but this is not common. This ap-
proach is supported by repeatmicrobiologic culture data from
our institution [7,9].
Study groups
All patients experienced VAP, were treated with appro-
priate definitive antibiotics, and survived the VAP episode.
Patients were categorized into one of three groups based on
complicating factors that could affect the resolution of clinical
evidence of disease. Patients with VAP who were treated
appropriately, did not acquire any other infections, and did
not have any of the complicating factors listed below were
placed in the uncomplicated VAP group. Patients with
complications that could relate to VAP, such as inadequate
empiric antibiotic therapy (IEAT), VAP relapse, VAP super-
infection, or acute respiratory distress syndrome (ARDS),
were placed in the complicated VAP group. Patients with
concurrent infection(s) at another site were placed in the
concurrent infection +VAP group.
Definitions
The adequacy of empiric therapy was determined for each
VAP episode. IEATwas defined as VAP caused by at least one
bacterial species reported to have either intermediate or full
in vitro resistance to all empirical antibiotics. Empiric antibi-
otic therapy was considered adequate if at least one antibiotic
in the regimen demonstrated in vitro activity against all
identified pathogens. The treating physician diagnosedARDS
using standard criteria that included acute onset, bilateral
infiltrates on chest radiograph, exclusion of cardiogenic pul-
monary edema, and a PaO2:FIO2 < 200 . Additional infections
were defined as follows: VAP relapse, a subsequent BAL
demonstrating growth of the original pathogen ‡ 100,000
CFU/mL; VAP superinfection, a subsequent BAL demon-
strating growth of a different pathogen ‡ 100,000 CFU/mL,
bacteremia/fungemia, growth from at least two bottles for
S. epidermidis or from one bottle for all other bacteria or fungi;
urinary tract infection (UTI), urine culture demonstrating
bacterial or fungal growth ‡ 100,000 CFU/mL; surgical site
infection, or any wound deemed infected by the treating sur-
geon and requiring antibiotic therapy.
Data collection
Demographic data, Injury Severity Score (ISS), duration of
mechanical ventilation, and length of stay in the TICU and
hospital were recorded. Patients were followed from the day
the BALwas conducted (Day 1) through Day 16. Patients who
were discharged from the ICU during the follow-up period
were included in the final analysis. Patients discharged from
the hospital are clinically stable. Therefore, unresolved clinical
abnormalities were considered resolved on the day of dis-
charge and were categorized as such through Day 16. The
following clinical and laboratory data were recorded daily:
Tmax, WBC count, and PaO2:FIO2. Resolution was defined as
follows: Tmax ‡ 36C or £ 38C, WBC count ‡ 4 · 103 cells/
mm3 or £ 10· 103 cells/mm3, and a PaO2:FIO2 ratio ‡ 250
[2,10]. The diagnosis of VAP does not require all disease fea-
tures be abnormal; thus, resolution for individual measures
was evaluated only in those patients with abnormal variables
on the day of diagnosis.
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Statistical analysis
Continuous variables were compared using the Student
t-test for normally distributed variables or theWilcoxon rank-
sum test for non-normally distributed variables. Proportions
were compared using the w2 test. Repeated-measures analysis
of variance was used to compare changes in clinical features
over the 16-day follow-up period for the three groups. Mul-
tiple pairwise comparisons were made using the Holm-Sidak
method. The Kaplan-Meier method was used to depict the
probability of resolution of clinical and laboratory abnor-
malities. The log-rank test was used to compare two Kaplan-
Meier curves. All statistics were calculated using SigmaPlot
11.1 software (Systat Software, Inc., San Jose, CA). Data are
presented as mean– standard deviation (SD), mean– 95%
confidence interval (95% CI), median (interquartile range), or
proportions, as indicated.
Results
A total of 142 patients with VAP were identified. Fifteen
patients were excluded because of death during antibiotic
therapy for VAP, and one was excluded because insufficient
information was available. Therefore, 126 patients were ana-
lyzed. Twenty-nine patients (23%) had no complications
during their VAP episode (uncomplicated VAP), whereas
69 patients (54.8%) experienced IEAT, a VAP relapse, super-
infection, or ARDS during their VAP episode (complicated
VAP). Twenty-eight patients (22.2%) had a concurrent UTI,
bacteremia, or surgical site infection during their VAP episode
(concurrent infection +VAP). Patient demographics were
similar in all three groups (Table 1). It was not surprising that
patients with complicated VAP had a significantly lower rate
of early VAP (p = 0.006) and a statistical trend toward a higher
ISS (p = 0.057).
The VAP pathogens are listed in Table 2. Of note, Haemo-
philus influenzae was the most common. Methicillin-resistant
S. aureus accounted for 7.4% of organisms overall, 7.4% in the
uncomplicated VAP group, 6.7% in the complicated VAP
group, and 9.5% in the concurrent infection +VAP group.
Overall, 90 patients (71%) underwent one surgical proce-
dure during the 16-day follow-up. This first operation was
performed on average 5.4 – 4.5 days (range 1–15 days) after
the diagnosis of VAP. Thirty-nine patients (31%) underwent a
second operation 7.4 – 4.1 days after VAP diagnosis, and
smaller numbers of patients underwent three, four, and five
surgical procedures (14, 7, and 3 patients, respectively). Op-
eration 1 occurred in 20 patients (69%) with uncomplicated
VAP, 51 (74%) with complicated VAP, and 19 (68%) with
concurrent infections +VAP. Operation 2 occurred in 10 pa-
tients (35%) with uncomplicated VAP, 23 (33%) of those with
complicated VAP, and six patients (21%) with concurrent in-
fections +VAP.
Changes in clinical and laboratory measures for all three
groups are depicted in Figure 1. In patients with un-
complicatedVAP and an elevated temperature at baseline, the
earliest statistically significant decrease in Tmax occurred on
Day 4 (Day 1: 39– 0.5C vs. Day 4: 38.6 – 0.7C, p = 0.028).
However, the group’s mean Tmax never dropped below 38C
(Day 16 mean Tmax 38.1 – 0.6C). Patients with complicated
VAP with an elevated baseline temperature demonstrated a
statistically significant decrease in Tmax at Day 2 (Day 1:
39.1 – 0.5C vs. Day 2: 38.7 – 0.8C; p = 0.047). Interestingly,
the mean Tmax normalized on Day 16 in this group (mean
38– 0.8C). In the concurrent infection +VAP group, Tmax
decreased significantly onDay 7 (Day 1: 39.2 – 0.5Cvs. Day 7:
38.5 – 0.7C; p = 0.005). The mean Tmax normalized on Day 13
(mean 38 – 0.8C), but then increased again and normalized
on Day 16 (mean 37.9 – 0.8C).
In patients with an elevated baselineWBC count, there was
no statistically significant change over the 16-day follow-up
(uncomplicated VAP p= 0.26; Complicated VAP p= 0.097;
concurrent infection +VAP p = 0.09), and the mean WBC
Table 1. Demographics of Study Patients by Group
Uncomplicated
VAP (n= 29)
Complicated
VAP (n= 69)
Concurrent infection
with VAP (n= 28) p valuea
Mean age (years – SD) 44.2 – 15.8 42.8 – 17.2 44.6 – 19.3 NS
Male/female 22/7 56/13 21/7 NS
Blunt injury, % (n) 86 (25) 84 (58) 75 (21) NS
Type of injury, % (n)
TBI 42 (12) 55 (38) 54 (15) NS
SCI 7 ( 2) 13 ( 9) 7 ( 2) NS
Fractures 79 (23) 68 (47) 54 (15) NS
Abdominal 35 (10) 43 (30) 43 (12) NS
Chest 45 (13) 45 (31) 54 (15) NS
Median Injury Severity Score (IQR) 26 (20–34) 34 (25–42) 31 (22–41) NS
Early VAP, % (n) 79 (23) 46 (32) 68 (19) 0.006
ARDS, % (n) 0 ( 0) 42 (29) 0 ( 0)
Subsequent BAL, % (n) 62 (18) 84 (58) 54 (15)
Microbiologic response on BAL, % (n) 100 (18) 52 (30) 100 (15)
Median days of mechanical ventilation (IQR) 17 (13–33) 24 (16–47) 18 (11–29) NS
Median ICU length of stay (IQR) 26 (18–42) 28 (20–49) 21 (16–36) NS
Median hospital length of stay (IQR) 35 (26–52) 36 (26–61) 33 (29–41) NS
aComparison between VAP only and VAP + confounders.
ARDS= acute respiratory distress syndrome; BAL= bronchoalveolar lavage; ICU = intensive care unit; IQR= interquartile range;
SCI = spinal cord injury; SD= standard deviation; TBI= traumatic brain injury; VAP=ventilator-associated pneumonia.
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count never normalized in any of the three groups. The
PaO2:FIO2 in the uncomplicated VAP and concurrent infec-
tion +VAP groups did not change significantly (p = 0.058 and
0.197, respectively), whereas the complicated VAP group
demonstrated a significant decrease at Day 3 (Day 1: 170 – 67
vs. Day 3: 246 – 158; p = 0.033). The PaO2:FIO2 fluctuated
by worsening on Days 4–6, but improving significantly on
Days 8, 9, 13, and 16.
The proportions of patients whose clinical and laboratory
abnormalities resolved on Days 3, 6, 9, 12, and 16 are pre-
sented in Table 3. The majority of patients in all three groups
did not achieve resolution by Day 6. Even by Day 16, reso-
lution was less common than had been expected. The proba-
bility of resolving all three abnormalities is displayed in
Figure 2. Kaplan-Meier log-rank analysis demonstrated no
significant difference between patients with uncomplicated
VAP, complicated VAP, and concurrent infection +VAP. In
addition, similar results were seen when patients were cate-
gorized according to the timing of VAP (early or late) or
whether the VAP was caused by non-fermenting gram-neg-
ative bacilli (data not shown).
Discussion
This retrospective study raises serious concerns about the
value of the traditional measures used to assess VAP treat-
ment in trauma patients. According to the current American
Thoracic Society/Infectious Diseases Society of America
(ATS/IDSA) guidelines [1], the uncomplicated VAP group
should have demonstrated a clear response to therapy by Day
3 and a substantive response by Day 6. However, in this
group, the Tmax was the only measure to decline significantly
during the 16-day follow-up. Although the decline was
statistically significant, it was likely not clinically significant,
being approximately 0.4C by Day 4. Indeed, the group mean
never normalized. The WBC count and PaO2:FIO2 never
declined significantly and never normalized. These findings
seem valid because the uncomplicated VAP group had no
concomitant infections or complicating factors related to VAP
that may have kept the clinical and laboratory abnormalities
from resolving. Also, all patients in this groupwere confirmed
to have had a positive microbiologic response to treatment
according to a follow-up BAL. Furthermore, the clinical
response did not differentiate patients with uncomplicated
VAP, complicated VAP, or concurrent infection +VAP. Tra-
ditional medical belief dictates that there probably would
have been a clear difference in the resolution of the clinical and
laboratory abnormalities in these groups. Unfortunately, in
these critically injured patients, resolution of all disease
measures was poor in each of the three groups (less than 35%
by Day 16) despite successful treatment of their VAP. Ad-
ditionally, the probability of resolution of all three measures
did not differ between groups. Overall, these results suggest
that the current guidelines do not apply well to trauma patients.
There are only a few studies that have evaluated this issue.
The study most similar in design to the current one was per-
formed by Dennesen et al. [2], but their results were different
from ours. They noted Tmax and WBC count declined and
Table 2. Pathogens Isolated from Patients with Ventilator-Associated Pneumonia
Pathogen
Uncomplicated
VAP (n = 29)
Complicated
VAP (n= 68)
Concurrent infection
with VAP (n = 28)
Total
(n = 126)
Gram-positive organisms
Methicillin-sensitive
Staphylococcus aureus
8 12 6 26
Methicillin-resistant S. aureus 4 8 4 16
Viridans Streptococcus 6 10 2 18
Streptococcus pneumoniae 4 5 5 14
Other streptococci 1 3 2 6
Methicillin-sensitive S. epidermidis 0 1 0 1
Methicillin-resistant S. epidermidis 0 1 0 1
Diphtheroids 1 3 1 5
Gram-negative organisms
Citrobacter koseri 1 0 0 1
Haemophilus influenzae 9 21 9 39
Haemophilus parainfluenzae 3 4 0 7
Acinetobacter baumannii 0 12 6 18
Pseudomonas aeruginosa 3 11 2 16
Proteus mirabilis 1 2 1 4
Escherichia coli 3 2 0 5
Enterobacter aerogenes 2 4 0 6
Enterobacter cloacae 0 3 0 3
Non-pathogenic Neisseria species 4 2 2 8
Achromabacter species 0 2 0 2
Aeromonas hydrophilia 0 1 0 1
Stenotrophomonas maltophilia 0 8 0 8
Serratia marcescens 0 2 0 2
Klebsiella pneumoniae 1 3 1 5
Branhamella catarrhalis 3 0 1 4
Total organisms 54 120 42 216
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the PaO2:FIO2 increased after VAP. However, it is important
to note that they enrolled medical, surgical, trauma, and
neurologic patients, whereas the current study included only
trauma patients. In addition, in the current study, the WBC
count and Tmax were higher, and the PaO2:FIO2 was lower, on
the day of VAP diagnosis than in the study by Dennesen et al.
(WBC 15.1 – 3.8 · 103 cells/mm3 vs. 14.2 – 5.4 · 103 cells/mm3,
Tmax 39 – 0.6C vs. 38.8 – 0.5C, PaO2:FIO2 176– 55 vs.
197 – 79). Perhaps the patients in the current study were more
seriously ill at the onset of infection. Moreover, Dennesen
et al. used a resolution cutoff for the PaO2:FIO2 of 188, which is
lower than that used in the current study and by others
[10,11]. Another difference is that the diagnostic criteria for
VAP in the current study were more rigorous. Dennesen et al.
did not define their diagnostic threshold, whereas the current
study used ‡ 100,000 CFU/mL, which is recommended in the
ATS/IDSA guidelines but is not accepted universally. Finally,
the paper by Dennesen et al. is somewhat confusing be-
cause they report a mean duration until resolution of six days
for all three signs, whereas their graph indicates that themean
WBC count never normalized.
Other studies were similar to the current study in showing
that clinical and laboratory abnormalities do not resolve
quickly or cleanly during VAP. A large randomized trial [12]
noted only a small decline inmean temperature after treatment
of VAP (Day 1*38.6C, Day 2*38.1C). Although the tem-
perature responded to antibiotic therapywithin three days, the
mean PaO2:FIO2 did not increase above 250 until after Day 7,
and the mean WBC count remained above 10· 103 cells/mcL
through Day 28.
A related issue is the possibility that IEAT or specific
pathogens can affect resolution of disease. Vidaur et al. re-
ported the clinical resolution of 60 patients with adequate
empiric therapy and 30 with inadequate therapy [10]. In-
adequate EAT delayed the median time to resolution of fever,
hypoxemia, and WBC count by 5–7 days, 6–8 days, and 3–5
days, respectively. Infection with MRSA increased the time to
resolution of disease regardless of IEAT status. These data
highlight additional factors that must be considered when
evaluating the treatment response. In the current study, pa-
tients experiencing IEAT were separated from those receiving
appropriate therapy. Patients with MRSA VAP were not
grouped separately because the incidence ofMRSAwas similar
in the three groups (uncomplicated VAP 7.4%, complicated
VAP 6.7%, and concurrent infection+VAP 9.5%). Thus, these
factors are unlikely to explain the delayed response seen in the
current study.
The lack of resolution in the current study likely is multi-
factorial. Surgery has been associated with elevations in
temperature andWBC count even if the patient does not have
an infection [13]. Thus, the multiple surgical procedures per-
formed in the study patients may have masked a clinical re-
sponse to antibiotics by altering temperature andWBC count.
Additionally, more than one-half of the patients had early
VAP (< 7 days), suggesting the presence of SIRS as a result of
their original trauma [4].
New methods must be identified for evaluating the re-
sponse of trauma patients to VAP therapy. Repeat BAL cul-
tures can be used [7,14] and were the standard of practice in
the current study. Unlike clinical measures, repeat cultures
are not affected by non-infectious variables and thus are a
more objective marker. Mueller et al. noted shorter durations
of antibiotic therapy when repeat BAL cultures were used [7].
Microbiologic data could reduce clinicians’ reliance on other
laboratory data, especially in trauma patients. However, re-
peat cultures are invasive and can be expensive, depending on
the techniques used. Alternatively, biomarkers such as pro-
calcitonin may be able to signal response to therapy [15], and
in one study this protein was not affected by surgery [16].
A recent meta-analysis of seven studies showed that pro-
calcitonin monitoring decreased the duration of antibiotics in
patients with respiratory tract infections [15].
FIG. 1. Mean values for clinical and laboratory measures
after diagnosis of ventilator-associated pneumonia. Day 1 is
the day bronchoalveolar lavage was conducted to verify the
pneumonia.
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The current study has several limitations. The data were
collected retrospectively, which is inherently less specific
than a prospective study. However, the variables were re-
corded accurately and would not have been different if col-
lected prospectively. Second, a diagnostic threshold for VAP
of ‡ 100,000 CFU/mL is higher than the ‡ 10,000 CFU/mL
used by many institutions. The larger bacterial load may re-
sult in a longer time to resolution of clinical and laboratory
abnormalities. Finally, the study enrolled only 29 patients in
the uncomplicated VAP group, which is the ideal study
group for this problem. Although this number is relatively
small, it is not substantially different from the enrollment in
other published studies evaluating resolution of disease [2,3].
Indeed, the total number of patients across the three groups is
good in relation to this body of literature. The strengths of the
study include a relatively homogeneous population, the use
of the highest-quality VAP diagnostic criteria, and a high
percentage of patients with follow-up cultures that confirmed
a positive response to treatment. The study enrolled only
critically injured patients, a population that is inherently
different from other critically ill patients. Use of broncho-
scopic BAL with quantitative cultures ensured that the pa-
tients actually had VAP and thus eliminates bias from
including patients without pneumonia.
Conclusion
Signs, symptoms, and laboratory abnormalities in critically
injured trauma patients with VAP do not resolve as quickly as
suggested by the guidelines. The probability of resolving all
three clinical measures does not differ in patients with un-
complicated VAP and those with complications or concurrent
infections. Future studies should evaluate new methods to
determine the response to antibiotic therapy in critically in-
jured patients with VAP.
Author Disclosure Statement
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Table 3. Resolution of Clinical Abnormalities
Day of resolution Uncomplicated VAP Complicated VAP Concurrent infection +VAP
Maximum temperature, % (n/total n)
Day 3 10.3 ( 3/29) 18 (11/61) 4.2 ( 1/24)
Day 6 27.6 ( 5/29) 24.6 (15/61) 16.7 ( 4/24)
Day 9 37.9 (11/29) 32.8 (20/61) 37.5 ( 9/24)
Day 12 55.2 (16/29) 42.6 (26/61) 37.5 ( 9/24)
Day 16 51.7 (15/29) 53.4 (35/61) 54.2 (13/24)
White blood cell count, % (n/total n)
Day 3 21.1 ( 4/19) 18.9 ( 7/37) 10.5 ( 2/19)
Day 6 21.1 ( 4/19) 10.8 ( 4/37) 31.6 ( 6/19)
Day 9 15.8 ( 3/19) 10.8 ( 4/37) 31.6 ( 6/19)
Day 12 26.3 ( 5/19) 16.2 ( 6/37) 15.8 ( 3/19)
Day 16 15.8 ( 3/19) 35.1 (13/37) 36.8 ( 7/19)
PaO2:FIO2, % (n/total n)
Day 3 29.2 ( 7/24) 33.9 (19/56) 40.9 ( 9/22)
Day 6 45.8 (11/24) 30.4 (17/56) 40.9 ( 9/22)
Day 9 33.3 ( 8/24) 41.1(23/56) 59.1 (13/22)
Day 12 29.2 ( 7/24) 51.8 (29/56) 40.9 ( 9/22)
Day 16 33.3 ( 8/24) 62.5 (35/56) 72.7 (16/22)
All abnormalities, % (n/total n)
Day 3 3.4 ( 1/29) 4.3 ( 3/69) 3.5 ( 1/28)
Day 6 10.3 ( 3/29) 4.3 ( 3/69) 0 ( 0/28)
Day 9 10.3 ( 3/29) 4.3 ( 3/69) 3.6 ( 1/28)
Day 12 10.3 ( 3/29) 7.2 ( 5/69) 7.1 ( 2/28)
Day 16 20.1 ( 6/29) 21.7 (15/69) 32.1 ( 9/28)
FIG. 2. Kaplan-Meier graph depicting the probability that
all three abnormalities (maximum temperature, white blood
cell count, and PaO2:FIO2) will not resolve over the 16-day
follow-up period. There was no difference in the probability
of non-resolution (p = 0.5).
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